---
title: "IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295051778.md"
description: "RBC Capital analyst Leonid Timashev maintained a Buy rating on IDEAYA Biosciences (IDYA) with a $48 price target, noting the stock closed at $36.11. This aligns with a broader Strong Buy consensus averaging $52.90 and a Wells Fargo Buy rating also set at $48."
datetime: "2026-08-06T01:47:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295051778.md)
  - [en](https://longbridge.com/en/news/295051778.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295051778.md)
generator: "portal-rs"
---

# IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital

In a report released on August 4, Leonid Timashev from RBC Capital maintained a Buy rating on IDEAYA Biosciences, with a price target of $48.00. The company’s shares closed yesterday at $36.11.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Timashev is a 5-star analyst with an average return of 24.0% and a 60.25% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Alkermes, and ADC Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IDEAYA Biosciences with a $52.90 average price target, a 46.50% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $48.00 price target.

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)](https://longbridge.com/en/news/296510282.md)
- [IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer | IDYA Stock News](https://longbridge.com/en/news/296337883.md)
- [Jefferies Sticks to Its Buy Rating for Covista (CVSA)](https://longbridge.com/en/news/296118987.md)
- [MDA Space Ltd (MDA) Receives a Buy from Morgan Stanley](https://longbridge.com/en/news/296117319.md)
- [Navan, Inc. Class A (NAVN) Receives a Buy from Jefferies](https://longbridge.com/en/news/296127841.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**